Senotherapeutix

Senotherapeutix is a preclinical-stage biotechnology company focused on the discovery and development of novel senotherapeutic agents to treat age-related diseases. The company leverages a proprietary drug discovery platform to identify small molecules that selectively eliminate senescent cells (senolytics) or modulate their pro-inflammatory secretions (senomorphics). By targeting the underlying biological process of cellular senescence, Senotherapeutix aims to address high-need indications such as idiopathic pulmonary fibrosis and chronic kidney disease. The company's approach is rooted in the emerging field of geroscience, seeking to extend healthy lifespan by delaying or reversing the progression of chronic degenerative conditions.